ESMO 2024 – iTeos TIGIT meets its efficacy criteria
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
ESMO 2024 – Nuvalent looks beyond its late-line Alkove
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
ESMO 2024 – MediLink impresses in small-cell lung cancer
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
ESMO 2024 – NiKang’s case for a better Welireg
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
ESMO 2024 – degraders disappoint again
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
ESMO 2024 – Bristol heads for phase 3 in small-cell
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Accelerated path closes for Moderna/Merck’s immunotherapy
Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.
